Virogin Biotech
PrivateLast Round
Series D
Sep 24, 2021
Total Funding Raised
$279M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Virogin Biotech operates in Healthcare & Life Sciences and is based in Richmond. Its latest recorded funding round was a Series D round in September 2021.
Virogin Biotech is a clinical-stage immuno-oncology company developing oncolytic virotherapy and mRNA-based therapeutics to elicit an anti-tumor immune response against solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Virogin Biotech Comparables
Compare Virogin Biotech with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Binhui Biopharmaceutical Co., Ltd. | 88% | |
| ImmVira | 87% | |
| TILT Biotherapeutics | 87% |
For institutional investors. Book with your work email.
Virogin Biotech Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 24, 2021 | ||||
| Series C | Sep 21, 2020 | ||||
| Series B | Dec 4, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Virogin Biotech Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Korea Investment Partners | Series C |
| 健壹资本 | Series B |
| SDIC Venture Capital | Series C |
| Panlin Capital | Series C, Series D |
| CDH Investments | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 47% MoM.
- Jul 26, 2026
Monthly visitors increased 93% MoM.
For institutional investors. Book with your work email.
Virogin Biotech Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Virogin Biotech's valuation, stock price, and market status.
Is Virogin Biotech a public or private company?
Virogin Biotech is a private company.
What is the current stock price of Virogin Biotech?
Virogin Biotech is a private company, so its shares have no public market price. Caplight tracks Virogin Biotech's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Virogin Biotech worth (valuation)?
Valuation information for Virogin Biotech is not publicly available.
Can I buy Virogin Biotech stock?
Virogin Biotech shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Virogin Biotech's last funding round?
Virogin Biotech's most recent funding round was Series D on September 24, 2021.
Who are the main investors in Virogin Biotech?
Key investors in Virogin Biotech include SDIC Venture Capital, CDH Investments.
Will Virogin Biotech IPO soon?
No public IPO plans have been announced for Virogin Biotech.
How can I track Virogin Biotech secondary market activity?
Caplight tracks bids, offers, and trades in Virogin Biotech's shares on secondary markets.